在三阴性乳腺癌中通过德西塔进行表观遗传重编程:机制,免疫调节和治疗协同作用
Fathima Raahima Riyas Mohamed1, Safiah Aldubaisi1, Arshiya Akbar1
1College of Medicine, Alfaisal University, Riyadh 50927, Saudi Arabia.
Cancers
|September 27, 2025
概括
德西塔通过重编程表观遗传学和增强抗瘤免疫力,对三阴性乳腺癌 (TNBC) 呈现有前途的表现. 进一步的研究将集中在患者选择和克服这种侵袭性癌症的抵抗机制上.
科学领域:
- 在瘤学瘤学.
- 癌症表观遗传学 癌症表观遗传学
- 免疫治疗是一种免疫疗法.
背景情况:
- 三重阴性乳腺癌 (TNBC) 是积极的,由于缺乏向治疗,结果不佳.
- 异常的DNA甲基化是TNBC病变发生的一个关键驱动因素.
- 作为一种DNA甲基转移酶抑制剂 (DNMTi),Decitabine通过重新激活瘤抑制剂和调节免疫力来提供潜在的作用.
研究的目的:
- 系统地审查临床前和临床证据关于desitabine在TNBC中的疗效.
- 评估德西的作用机制和转化潜力.
- 识别耐药机制和未来的治疗策略.
主要方法:
- 在2025年4月之前,在主要数据库中进行PRISMA-2020合规文献搜索.
- 包括在TNBC临床前或临床环境中评估decitabine的研究.
- 使用QUIPS和RoB 2.0工具进行偏差风险评估.
主要成果:
- 在体外,德西塔诱导了生长抑制,细胞亡和沉默基因 (例如BRCA1,CDH1) 的重新表达.
- 在体内,德平降低了瘤负担并增强了抗瘤免疫力 (MHC-I,PD-L1,STING).
- 与抗PD-1,HDAC抑制剂和化疗观察到的协同效应;与DNMT活性,低DCK和miR-155相关的耐药性.
结论:
- 德西塔对TNBC具有显著的临床前和早期临床潜力.
- 表观遗传重编程和免疫激活是作用的关键机制.
- 未来的策略需要基于生物标志物的患者选择和耐药性的缓解.
相关概念视频
02:57Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
02:50Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K
02:56Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
02:49Cancer Therapies
9.8K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.8K